ArticleCell proliferation2026
Downregulation of MLL1 Promotes Intestinal Epithelial Barrier Repair Through Gata4/Bmp4 Activation to Ameliorate Crohn's Disease-Like Colitis in Mice.
Article in Cell proliferation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The dysfunctional reconstitution of the intestinal barrier is pivotal in driving the initiation of inflammatory pathogenesis in Crohn's disease (CD), although the exact pathophysiology underlying this phenomenon has yet to be definitively characterised. This study aimed to investigate the role of the histone methyltransferase mixed lineage leukaemia 1 (MLL1) in the development of CD-like colitis and to elucidate the mechanism by which MLL1 promotes epithelial cell differentiation. Colonic tissue specimens from CD patients and TNBS-induced murine models were analysed to assess MLL1 expression dynamics. The functional impact of MLL1 on murine colitis modelling CD was systematically investigated through clinical symptom scoring, histopathological profiling and quantitative evaluation of intestinal barrier integrity. The role of MLL1 in promoting epithelial cell differentiation and repairing the intestinal barrier was investigated through immunofluorescence and western blotting. Additionally, potential mechanisms underlying the reparative effects of MLL1 on intestinal barrier function were explored. MLL1 expression was upregulated in colonic tissues from CD patients and TNBS-induced murine colitis models. In contrast, MLL1 suppression in the TNBS cohort attenuated mucosal inflammation and downregulated pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α) within the colonic mucosa. Additionally, reduced MLL1 expression increased the differentiation capacity of intestinal epithelial cells, including goblet cells, absorptive cells and tuft cells, and promoted barrier function restoration in injured colons and lipopolysaccharide-stimulated colonic organoids. MLL1 downregulation activated the Gata4/Bmp4 signalling pathway, which may contribute to the reparative effects of MLL1 on intestinal barrier integrity. Downregulating MLL1 expression promotes intestinal epithelial cell differentiation by activating the Gata4/Bmp4 pathway. These findings elucidate a pathophysiological mechanism wherein MLL1 suppression potentiates intestinal barrier restoration, thereby attenuating colitis severity in murine models. The observed therapeutic efficacy positions MLL1 inhibition presents a novel strategy for CD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.